-
effectivehealthcare.ahrq.gov/sites/default/files/12_pregnancy_potential_high_impact_june_2012.pdf
January 01, 2012 - by week,” which is a Web-based information venue requiring fast Internet
connectivity. … the procedure is intended to correct the defect in the fetus, typically between the 19th and
26th week … Available:
http://www.mayoclinic.com/health/pregnancy-
week-by-week/MY00331.
14. Pregnancy. … prenatalcare.html
http://www.nlm.nih.gov/medlineplus/prenatalcare.html
http://www.mayoclinic.com/health/pregnancy-week-by-week … /MY00331
http://www.mayoclinic.com/health/pregnancy-week-by-week/MY00331
http://www.marchofdimes.com/
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/gerd-2005_executive.pdf
January 01, 2005 - Layout 1
Background
Gastroesophageal reflux disease (GERD),
defined as weekly heartburn and/or acid
regurgitation, is one of the most common
health conditions affecting older
Americans. Direct costs attributable to
GERD were estimated to be $10 billion in
the United States in 2000.
Some patients have frequent, sever…
-
effectivehealthcare.ahrq.gov/sites/default/files/implementation-package-unhealthy-alcohol-use-final.pdf
September 01, 2018 - Heavy drinking among U.S. adults, 2016: >14 drinks per week for men or >7 drinks
per week for women. … Institute on Alcohol Abuse and Alcoholism
recommends no more than 4 drinks per day and 14 drinks per week … Heavy drinking among U.S. adults, 2016: >14 drinks per week for men or >7 drinks per
week for women … For women and anyone 65 and older, they recommend no more than 3 drinks per day and 7 drinks
per week … Skyy answers that she has up to 5 mixed vodka drinks in a day at least 2-3 days a week.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-evidence-summary-2022-update_0.pdf
January 01, 2022 - Evidence Summary_Comparative Effectiveness Review No. 250_Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2022 Update
Comparative Effectiveness Review
Number 250
Living Systematic Review on Cannabis and
Other Plant-Based Treatments for Chronic
Pain: 2022 Update
Evide…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-234-headaches-pregnancy-revised-comments.pdf
November 12, 2020 - posted to the EHC Program Web
site or AHRQ Web site in draft form for public comment for a 3- to 4-week
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/evidence-summary-cer-202-bronchial-thermoplasty-asthma.pdf
December 01, 2017 - BT-treated patients than in
patients receiving sham treatment and/or standard care
during the 12-week
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/depression-treatment-ssri_surveillance.pdf
January 01, 2013 - adults
18 to 70
years old
Augmentation
with exercise
Exercise
expending 16
kcal per kg
per week
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-executive-summary-2023-update.pdf
January 01, 2023 - Executive Summary - Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2023 Update
Comparative Effectiveness Review
Number 250
Living Systematic Review on Cannabis
and Other Plant-Based Treatments for
Chronic Pain: 2023 Update
Executive Summary
Main Points
…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-211-rheumatoid-arthritis-disposition-comments.pdf
December 20, 2018 - This
review was posted for 52 days with a 1-week holiday-related extension. … We
have added the 24-week primary outcomes to the
Results section as suggested. … group than
for the MTX group at week 104 (p=0.038), but not at week 52
(p=NS). … At week 104,
Thank you for the information. … 24
with Actemra combination therapy and were maintained
through week 52.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/psoriasis-chronic_disposition-comments.pdf
November 27, 2012 - effectiveness research review is
posted to the EHC Program Web site in draft form for public comment for a 4-week … A 52-
week trial comparing briakinumab with
methotrexate in patients with psoriasis. … It should be
acknowledged that it is commonplace for dermatologists to compare 12-week
response rates … other end of the spectrum is phototherapy, which requires 2-3 visits to the
doctor’s office each week … PASI should be given for all time points, i.e. baseline, week 12 and
week 24.
-
effectivehealthcare.ahrq.gov/sites/default/files/diabetes-update-2015_disposition-comments.pdf
January 01, 2015 - Each research review is posted to the EHC Program
Web site in draft form for public comment for a 4-week … Hollander at al. evaluated Saxagliptin added to TZD to
assess efficacy at week 24. … ) extension of a 52-week
randomised controlled trial. … study 52 week addition of
DeFronzo 2009 data is from 24 week study 52 week
This data was included … Nauck
2011 reported 52 Week data Nauck 2014 reported
104 week data
We have fixed this reference.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/insomnia_disposition-comments.pdf
December 30, 2015 - Each research review is posted to the EHC Program
Web site in draft form for public comment for a 4-week … It
is open to debate whether two week and four week durations
are really so different in this context … All of that said, two
week studies were included in the previous meta-analyses. … The zolpidem was supplied 3-5 times per
week and contrasted with placebo. … 12 when treatment was
discontinued to 53% at week 16.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/mat-retention-strategies-rapid-review-1.pdf
August 01, 2020 - prison (3) in
an OTP or (4) in the CHC
Post-release: titrated dose
to 8 mg/day, then 16 mg
3x/week … One time per week based
on adherence the prior
week. … One time
per week based on
adherence the prior week. … stabilization, 2
week taper)
Retention: # of SMM
(standard medical
management) visits
Phase 2 … : 16 weeks
(12 week treatment,
4 week taper)
SMM + ODC (opioid
drug counseling)
vs
SMM alone
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-surveillance-report-3_0.pdf
May 01, 2022 - clinicaltrials.gov*".so.
16 11 or 12 or 13 or 14 or 15
17 10 not 16
Database: APA PsycInfo 1806 to January Week … THC:CBD oromucosal spray as add-on
measure in patients with severe chronic
pain: analysis of 12-week
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-apps-a-e-surveillance-report-2-final_0_0.pdf
March 01, 2022 - *".so.
16 11 or 12 or 13 or 14 or 15
17 10 not 16
Database: APA PsycInfo 1806 to September Week … oromucosal spray as add-on
measure in patients with severe chronic
I-15
pain: analysis of 12-week
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2024-surv-rep-update-executive-sum.pdf
January 01, 2024 - Executive summary_Comparative Effectiveness Review No. 250_Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2024 Update
Comparative Effectiveness Review
Number 250
Living Systematic Review on Cannabis
and Other Plant-Based Treatments for
Chronic Pain: 2024 Update
Exec…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-276-ocd-appendix-h.xlsx
January 01, 2023 - Design
Appendix H. Key Question 2 Predictors
Table H-1. KQ2 Predictors of Treatment Efficacy
PMID First Author Publication Year Extractor Study Name/Database/RCT PMID/Site Followup Duration N Mean Age (SD) Baseline CY-BOCS Score, Mean (SD) Intervention Type Pharmacolgical Interventions, Drug Class (e.g., SSRI) Phar…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2025-surv-rep-update-executive-sum.pdf
January 01, 2025 - dose 23 mg
THC/21 mg CBD daily
Inhaled cannabis:
Maximum of three 150
mg capsules per day in
week
-
effectivehealthcare.ahrq.gov/sites/default/files/13_pulmonary_potential_high_impact_june_2012.pdf
January 01, 2012 - as 2 weeks, and a
statistically significant treatment effect was reported to be maintained through week … Also through week 48, investigators reported, patients given ivacaftor were 55% less likely
to have … second measurement that was 10.6 percentage points
higher than patients treated with placebo through week … function were observed as early as 2 weeks, and a significant treatment effect was maintained
through week … Also through week 48, patients given ivacaftor were 55% less likely to have a
pulmonary exacerbation
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/hepatitis-c-treatment-adherence_executive.pdf
September 22, 2011 - The public was invited to comment on these
Key Questions during a 4-week period.